Verheijen RH - Search Results

1

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01.

Prinssen HM, Molthoff CF, Verheijen RH, Broadhead TJ, Kenemans P, Roos JC, Davies Q, van Hof AC, Frier M, den Hollander W, Wilhelm AJ, Baker TS, Sopwith M, Symonds EM, Perkins AC. Prinssen HM, et al. Among authors: verheijen rh. Cancer Immunol Immunother. 1998 Sep;47(1):39-46. doi: 10.1007/s002620050502. Cancer Immunol Immunother. 1998. PMID: 9755877

2

Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.

van Hof AC, Molthoff CF, Davies Q, Perkins AC, Verheijen RH, Kenemans P, den Hollander W, Wilhelm AJ, Baker TS, Sopwith M, Frier M, Symonds EM, Roos JC. van Hof AC, et al. Among authors: verheijen rh. Cancer Res. 1996 Nov 15;56(22):5179-85. Cancer Res. 1996. PMID: 8912854

3

Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study.

Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH. Molthoff CF, et al. Among authors: verheijen rh. Cancer. 1997 Dec 15;80(12 Suppl):2712-20. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2712::aid-cncr50>3.3.co;2-m. Cancer. 1997. PMID: 9406729 Clinical Trial.

4

An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma.

Davies Q, Perkins AC, Roos JC, Molthoff CF, Verheijen RH, Frier M, Kenemans P, Broadhead T, Sopwith M, Symonds EM. Davies Q, et al. Among authors: verheijen rh. Br J Obstet Gynaecol. 1999 Jan;106(1):31-7. doi: 10.1111/j.1471-0528.1999.tb08081.x. Br J Obstet Gynaecol. 1999. PMID: 10426256

5

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

van Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH. van Zanten-Przybysz I, et al. Among authors: verheijen rh. J Nucl Med. 2000 Jul;41(7):1168-76. J Nucl Med. 2000. PMID: 10914906 Free article.

6

Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.

van Zanten-Przybysz I, Molthoff CF, Roos JC, Verheijen RH, van Hof A, Buist MR, Prinssen HM, den Hollander W, Kenemans P. van Zanten-Przybysz I, et al. Among authors: verheijen rh. Int J Cancer. 2001 Apr 1;92(1):106-14. Int J Cancer. 2001. PMID: 11279613 Free article. Clinical Trial.

7

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study.

van Zanten-Przybysz I, Molthoff C, Gebbinck JK, von Mensdorff-Pouilly S, Verstraeten R, Kenemans P, Verheijen R. van Zanten-Przybysz I, et al. J Cancer Res Clin Oncol. 2002 Sep;128(9):484-92. doi: 10.1007/s00432-002-0348-z. Epub 2002 Aug 23. J Cancer Res Clin Oncol. 2002. PMID: 12242512 Clinical Trial.

8

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. Moreno M, et al. Among authors: verheijen rh. Cancer Lett. 2007 Nov 8;257(1):47-55. doi: 10.1016/j.canlet.2007.06.016. Epub 2007 Aug 9. Cancer Lett. 2007. PMID: 17692456

9

Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer.

Massuger LF, Thomas CM, Segers MF, Corstens FH, Verheijen RH, Kenemans P, Poels LG. Massuger LF, et al. Among authors: verheijen rh. J Nucl Med. 1992 Nov;33(11):1958-63. J Nucl Med. 1992. PMID: 1432156 Free article.

10

Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice.

Massuger LF, Boerman OC, Corstens FH, Verheijen RH, Claessens RA, Poels LG, van den Broek WJ, Kenemans P. Massuger LF, et al. Among authors: verheijen rh. Anticancer Res. 1991 Nov-Dec;11(6):2051-7. Anticancer Res. 1991. PMID: 1776839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page